MX2012000682A - Formas de bases libres cristalinas de un compuesto de bifenilo. - Google Patents

Formas de bases libres cristalinas de un compuesto de bifenilo.

Info

Publication number
MX2012000682A
MX2012000682A MX2012000682A MX2012000682A MX2012000682A MX 2012000682 A MX2012000682 A MX 2012000682A MX 2012000682 A MX2012000682 A MX 2012000682A MX 2012000682 A MX2012000682 A MX 2012000682A MX 2012000682 A MX2012000682 A MX 2012000682A
Authority
MX
Mexico
Prior art keywords
crystalline
crystalline freebase
biphenyl compound
freebases
freebase forms
Prior art date
Application number
MX2012000682A
Other languages
English (en)
Inventor
Grahame Woollam
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562758&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012000682(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of MX2012000682A publication Critical patent/MX2012000682A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Dos formas de bases libres cristalinas del éster 1-(2-[4-(4-carbamilpiperidin-l-ilmetil)benzoíl]metilamino}etil)pi peridin-4-ílico de ácido bifenil-2-ilcarbámico. Composiciones farmacéuticas que comprenden estas bases libres cristalinas o que se preparan usando estas bases libres cristalinas. Procesos e intermediarios para preparar estas bases libres cristalinas. Métodos para usar estas bases libres cristalinas en el tratamiento de los trastornos pulmonares.
MX2012000682A 2009-07-15 2010-07-14 Formas de bases libres cristalinas de un compuesto de bifenilo. MX2012000682A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22580309P 2009-07-15 2009-07-15
PCT/US2010/041903 WO2011008809A1 (en) 2009-07-15 2010-07-14 Crystalline freebase forms of a biphenyl compound

Publications (1)

Publication Number Publication Date
MX2012000682A true MX2012000682A (es) 2012-02-28

Family

ID=42562758

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000682A MX2012000682A (es) 2009-07-15 2010-07-14 Formas de bases libres cristalinas de un compuesto de bifenilo.

Country Status (21)

Country Link
US (11) US8541451B2 (es)
EP (2) EP2987490B1 (es)
JP (4) JP5651174B2 (es)
KR (1) KR101742252B1 (es)
CN (1) CN102470130B (es)
AU (1) AU2010273514B2 (es)
BR (1) BR112012000890A2 (es)
CA (2) CA2989129C (es)
DK (1) DK2453894T3 (es)
ES (2) ES2639642T3 (es)
HK (2) HK1168050A1 (es)
HR (1) HRP20151344T1 (es)
HU (1) HUE026414T2 (es)
IL (1) IL216995A (es)
MX (1) MX2012000682A (es)
PL (2) PL2453894T3 (es)
PT (1) PT2453894E (es)
SG (2) SG10201407913UA (es)
SI (1) SI2453894T1 (es)
SM (1) SMT201600019B (es)
WO (1) WO2011008809A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
MX2012000682A (es) 2009-07-15 2012-02-28 Theravance Inc Formas de bases libres cristalinas de un compuesto de bifenilo.
SG186708A1 (en) 2010-07-13 2013-02-28 Theravance Inc Process for preparing a biphenyl-2-ylcarbamic acid
RU2619944C2 (ru) * 2013-02-21 2017-05-22 Пфайзер Инк. Твердые формы селективного ингибитора CDK4/6
WO2015070366A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
CN112694434B (zh) * 2020-12-29 2023-06-16 浙江和泽医药科技股份有限公司 一种雷芬那辛新中间体及其活性亲电砌块和雷芬那辛的新制备方法
CN118401497A (zh) 2021-12-09 2024-07-26 医药化学公司 雷芬那辛的结晶型丙酮溶剂化物
CN114276290B (zh) * 2021-12-24 2024-05-28 浙江和泽医药科技股份有限公司 一种雷芬那辛无水晶型及其制备方法
CN117263849A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛三水合物晶型及其制备方法
CN117263848A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛的吸入喷雾剂
CN117180235A (zh) * 2023-09-19 2023-12-08 山东京卫制药有限公司 一种无定型雷芬那辛吸入制剂

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2425983C3 (de) * 1973-06-12 1978-09-14 Toyama Chemical Co. Ltd., Tokio Sulfonsäuresalze von Acylcholinen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
NO166268C (no) 1985-07-30 1991-07-03 Glaxo Group Ltd Innretning for administrering av medikamenter til pasienter.
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
SK280967B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
WO1992022286A1 (en) 1991-06-12 1992-12-23 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
US5337740A (en) 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
ATE204743T1 (de) 1991-12-18 2001-09-15 Minnesota Mining & Mfg Aerosolzusammensetzungen für arzneimittelsuspensionen
US5239993A (en) 1992-08-26 1993-08-31 Glaxo Inc. Dosage inhalator providing optimized compound inhalation trajectory
US5415162A (en) 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device
WO1995021820A1 (fr) 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive du carbamate et composition correspondante
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5637820A (en) * 1995-01-06 1997-06-10 Wittman; Kenneth L. Stringed instrument with on-board tuner
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
EP1366777B1 (en) 1995-04-14 2005-06-15 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
DE69918422T2 (de) 1998-03-14 2005-08-11 Altana Pharma Ag Phthalazinone als PDE3/4 Inhibitoren
AR018183A1 (es) 1998-04-18 2001-10-31 Glaxo Group Ltd Formulacion terapeutica en aerosol que comprende un agente terapeutico en la forma de particulas recubiertas por lo menos por un excipiente derecubrimiento y por lo menos un surfactante, en suspension en un gas propelente licuado para la administracion de agentes terapeuticos particularmentepor la r
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
EP1169019B1 (en) 1999-04-14 2003-02-26 Glaxo Group Limited Pharmaceutical aerosol formulation
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US7144908B2 (en) 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
DE60224172T2 (de) 2001-03-22 2008-12-04 Glaxo Group Ltd., Greenford Formanilid-derivative als beta2-adrenorezeptor-agonisten
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
KR100912324B1 (ko) 2001-09-14 2009-08-14 글락소 그룹 리미티드 호흡기 질환 치료용 펜에탄올아민 유도체
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
PE20050973A1 (es) * 2003-10-29 2005-11-19 Theravance Inc Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TW200540154A (en) * 2004-06-10 2005-12-16 Theravance Inc Crystalline form of a substituted pyrrolidine compound
US20060205949A1 (en) * 2005-03-10 2006-09-14 Theravance, Inc. Crystalline forms of a biphenyl compound
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
US7465870B1 (en) * 2008-03-11 2008-12-16 Homan Randy W Illuminated heart-shaped guitar with strobe lights and a modified bridge
MX2012000682A (es) * 2009-07-15 2012-02-28 Theravance Inc Formas de bases libres cristalinas de un compuesto de bifenilo.
SG186708A1 (en) 2010-07-13 2013-02-28 Theravance Inc Process for preparing a biphenyl-2-ylcarbamic acid

Also Published As

Publication number Publication date
US11691948B2 (en) 2023-07-04
CA2989129A1 (en) 2011-01-20
JP2012533550A (ja) 2012-12-27
CN102470130A (zh) 2012-05-23
HK1219415A1 (zh) 2017-04-07
HK1168050A1 (zh) 2012-12-21
US11649209B2 (en) 2023-05-16
US10100013B2 (en) 2018-10-16
US20110015163A1 (en) 2011-01-20
JP6338505B2 (ja) 2018-06-06
ES2639642T3 (es) 2017-10-27
US11008289B2 (en) 2021-05-18
JP2017171692A (ja) 2017-09-28
AU2010273514A1 (en) 2012-01-19
WO2011008809A1 (en) 2011-01-20
DK2453894T3 (en) 2016-01-25
US8541451B2 (en) 2013-09-24
US20230303492A1 (en) 2023-09-28
CA2765621A1 (en) 2011-01-20
US20180186740A1 (en) 2018-07-05
CA2765621C (en) 2018-02-13
IL216995A0 (en) 2012-02-29
US20200308116A1 (en) 2020-10-01
ES2557553T3 (es) 2016-01-27
EP2453894B1 (en) 2015-11-04
US10550081B2 (en) 2020-02-04
HRP20151344T1 (hr) 2016-01-01
HUE026414T2 (hu) 2016-05-30
JP2016026214A (ja) 2016-02-12
US20160143897A1 (en) 2016-05-26
SG178036A1 (en) 2012-03-29
US20190248743A1 (en) 2019-08-15
SI2453894T1 (sl) 2016-02-29
US20130338191A1 (en) 2013-12-19
PL2453894T3 (pl) 2016-04-29
US9226896B2 (en) 2016-01-05
AU2010273514B2 (en) 2015-01-22
PL2987490T3 (pl) 2017-12-29
US20150164796A1 (en) 2015-06-18
EP2987490B1 (en) 2017-06-14
US20170081283A1 (en) 2017-03-23
IL216995A (en) 2017-10-31
US8921396B2 (en) 2014-12-30
US20220009890A1 (en) 2022-01-13
US9765028B2 (en) 2017-09-19
EP2987490A1 (en) 2016-02-24
US11858898B2 (en) 2024-01-02
CA2989129C (en) 2021-03-09
SG10201407913UA (en) 2015-01-29
US9415041B2 (en) 2016-08-16
KR20130027004A (ko) 2013-03-14
PT2453894E (pt) 2016-02-02
US20220306580A1 (en) 2022-09-29
SMT201600019B (it) 2016-02-25
EP2453894A1 (en) 2012-05-23
JP2015003929A (ja) 2015-01-08
BR112012000890A2 (pt) 2017-10-31
CN102470130B (zh) 2013-09-04
KR101742252B1 (ko) 2017-05-31
JP5651174B2 (ja) 2015-01-07

Similar Documents

Publication Publication Date Title
MX2012000682A (es) Formas de bases libres cristalinas de un compuesto de bifenilo.
MX2007011083A (es) Formas cristalinas de un compuesto bifenilo.
WO2007127297A3 (en) Crystalline forms of a dimethylphenyl compound
ZA201201974B (en) Method for the preparation of 2,5-furandicarboxylic acid and for the prepartion of the dialkyl ester of 2,5-furandicarboxylic acid
WO2009139817A3 (en) Crystalline pharmaceutical and methods of preparation and use thereof
MX2010006179A (es) Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico.
WO2011127290A3 (en) Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
BR112013000877A2 (pt) processo para a preparação de um ácido bifenil-2-il carbâmico
WO2014188453A3 (en) Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid
MY150280A (en) Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
MX2013003558A (es) Sales de oxalato cristalinas de un compuesto diamida.
WO2010140765A2 (ko) 로수바스타틴의 신규한 제조방법, 이 제조에 유용한 중간체 화합물 및 그의 제조방법
MX350862B (es) Acidos de piperidinil naftilacetico.
MX2012007868A (es) Metodo para preparar sales de acido tetrazol-mentasulfonico, y un nuevo compuesto utilizado en las mismas.
PT2462098E (pt) Processos para a preparação de derivados de ácido 1-(2- halobifenil-4-il)-ciclopropanocarboxílico
WO2009118589A3 (en) Orally disintegrating compositions of rhein or diacerein
CL2011000093A1 (es) Compuestos derivados de un ester piperidinilico del acido bifenil-2-ilcarbamico; composicion farmaceutica; combinacion farmaceutica; y su uso para broncoconstriccion, enfermedades obstructivas o inflamatorias de las vias respiratorias.
MX2012002818A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
MY150817A (en) Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
MX2010009926A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico.
WO2011027359A3 (en) Process for the preparation of 4 -hydroxy atomoxetine and intermediates in the manufacture thereof
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
GB0813270D0 (en) Process of preparing optically active B-hydroxycarboxylic acid derivative
IL215550A (en) Process for the preparation of a biphenyl ester 2-carboxylic acid moiety 1– [2–2] -chloro-4-formyl-5-methoxyphenyl) -carbamoylethyl] piperidene-4 ester yl and intermediate
WO2011128699A3 (en) Novel process for the preparation of sunitinib

Legal Events

Date Code Title Description
FG Grant or registration